AbinoNutra is a U.S.-based longevity nutrition brand under Abinopharm, Inc., founded in 2020 and headquartered in Connecticut.
Focused on clinically studied NMN and NR, AbinoNutra integrates human research, cGMP-certified manufacturing, and rigorous quality standards to deliver affordable, science-backed NAD⁺ support.
Through transparent sourcing, compliant production, and evidence-based formulation, the brand is committed to making high-quality longevity science accessible to everyday consumers worldwide.
Every cell in your body depends on NAD+ (nicotinamide adenine dinucleotide) to function properly. This coenzyme is essential for helping convert the food you eat into ATP—the energy currency that powers all cellular activities. Without adequate NAD+, your cells can't meet their energy demands.
Scientists have identified two primary ways this molecule supports cellular health, both of which become increasingly important as we age.
Energy Production
NAD+ facilitates cellular energy creation through redox reactions, cycling between its oxidized form (NAD+) and reduced form (NADH). This process is essential for the three major metabolic pathways that produce ATP: glycolysis breaks down glucose, the citric acid cycle (also known as the Krebs cycle) processes metabolic intermediates, and fatty acid oxidation breaks down fats—all generating the ATP that fuels every cellular process.
Cellular Maintenance and Repair
NAD+ also activates sirtuins—specialized enzymes that help regulate your body's cellular maintenance system. Sirtuins require NAD+ to regulate gene expression, support cellular cleanup processes (autophagy), maintain circadian rhythms, repair DNA, and coordinate stress responses.
Your body obtains NAD+ building blocks from dietary sources like tryptophan and niacin (vitamin B3), and maintains a recycling system called the salvage pathway to reuse NAD+ components. However, these natural mechanisms may not produce sufficient levels to meet your cells' increasing energy demands in tissues, such as in muscle, brain and heart, especially as you age.
Research shows that NAD+ deficiency develops through three interconnected factors that intensify over time and contribute to recognized hallmarks of aging:
• Decreased cellular NAD+ synthesis
• Increased cellular NAD+ consumption
• Consistent exposure to metabolic stressors
Tissues with the greatest metabolic demands are likely to be most affected by NAD+ depletion, offering a potential explanation as to why certain age-related changes become noticeable first:
• Brain Health
• Cardiovascular Health
• Muscle Health
While your body's natural NAD+ production and recycling systems work continuously, they may become increasingly inadequate with age and metabolic stress. Not all NAD+ precursors are created equal—your cells have specific pathways and limitations for converting these molecules into usable NAD+.
β-Nicotinamide Mononucleotide (NMN)/Nicotinamide riboside (NR) offers a uniquely efficient route to NAD+ replenishment
Unlike direct NAD+ supplementation, which faces absorption challenges due to the molecule's size and instability, this targeted approach to restoring NAD+ levels can help bridge the critical energy gap, leading to:
• Supported cellular energy production
• Maintenance of cellular repair
• Supported metabolic efficiency
AbinoNutra is backed by Abinopharm’s expertise across active pharmaceutical ingredients, compounded medicines, generics, biosimilars, NDA programs, regulatory filings, and healthy-longevity research.
Years of combined biotech, pharmaceutical, and healthcare experience.
*API programs across commercial, DMF-filed, and R&D stages.
Generic and biosimilar drug products in the U.S. approval and filing pipeline.
Pharmaceutical pathways spanning compounding, generics, biosimilars, and NDA development.
AbinoNutra® is built around clinically studied NAD⁺ support, including published human NMN research and broader human evidence on NAD⁺ precursors. These studies help ground the formula story in measurable human data, including NAD⁺ response, tolerability, and healthy-aging related outcomes.
A randomized, multicenter, double-blind, placebo-controlled GeroScience study evaluating 300 mg, 600 mg, and 900 mg NMN over 60 days.
A post-hoc analysis exploring individual NAD⁺ response patterns after NMN supplementation.
A GeroScience post-hoc analysis examining associations between blood NAD⁺ levels and laboratory markers.
The original NMN study received Third Prize in the 2024 GeroScience Outstanding Original Research Paper Award.
AbinoNutra® pairs clinically researched ingredients with documented safety, regulatory, and manufacturing quality signals. From NAD⁺ precursors to cellular-protection nutrients, its ingredient platform is supported by external safety reviews, FDA GRAS records, and industry-published quality documentation.
FDA GRN 635 documents nicotinamide riboside chloride as a source of vitamin B3.
EFSA published safety opinions on nicotinamide riboside chloride as a novel food and source of niacin.
FDA GRN 1191 lists Dr.Ergo® L-Ergothioneine, with FDA’s public “no questions” response letter.
SGS Nutrasource reported that an independent expert panel agreed with the GRAS conclusion for Dr.Ergo® L-Ergothioneine.
Nutraceutical Business Review covered the FDA GRAS milestone for Dr.Ergo® Ergothioneine.
